Physician profile
Christopher M Frank
NPI 1699942474
$12,073.51
in general payments reported to CMS, 2019-2025
25 companies · $3,948 in 2025
The $3,948 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $131 · 2021: $71.93 · 2022: $637 · 2023: $1,778 · 2024: $5,026 · 2025: $3,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,734 · Travel and Lodging: $4,143 · Consulting Fee: $1,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,734.01 |
| Travel and Lodging | $4,143.32 |
| Consulting Fee | $1,874.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $3,859.42 | 2019-2025 | Carto 3 |
| Boston Scientific Corporation | $2,599.76 | 2019-2025 | Watchman Flx, General - Therapies, Cds Broad Portfolio Offering |
| Medtronic, INC. | $2,227.06 | 2023-2025 | Evera Mri Xt Dr Surescan, Selectsecure, Aurora Ev-Icd Mri Surescan |
| Abbott Laboratories | $1,516.42 | 2022-2025 | Aveir, Ensite |
| Novartis Pharmaceuticals Corporation | $439.24 | 2019-2025 | |
| Cvrx, INC. | $232.11 | 2022 | |
| Kestra Medical Technology Services, INC. | $163.80 | 2023-2024 | Assure Wcd |
| Pfizer INC. | $132.55 | 2023-2025 | |
| Amgen INC. | $131.85 | 2021-2024 | Repatha |
| Cardiva Medical, INC. | $122.45 | 2024-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Optowire, Cardiva Vascade Mvp Vvcs 6-12f |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.36 | 2023-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $84.93 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $83.51 | 2020-2024 | Xarelto |
| Novo Nordisk INC | $70.08 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.22 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $46.31 | 2019-2023 | |
| Lundbeck LLC | $38.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.14 | 2019-2023 | Camzyos |
| Teleflex LLC | $33.93 | 2024 | Guideliner |
| Bayer Healthcare Pharmaceuticals INC. | $22.15 | 2025 | |
| Atricure, INC. | $18.95 | 2023 | |
| Biotronik INC. | $14.50 | 2019 | |
| Braemar Manufacturing, LLC | $14.18 | 2019 | |
| Medtronic Vascular, INC. | $11.77 | 2020 | |
| Altathera Pharmaceuticals LLC | $6.06 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.